Titre : Éphrine A3

Éphrine A3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Éphrine A3 : Questions médicales les plus fréquentes", "headline": "Éphrine A3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Éphrine A3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-21", "dateModified": "2025-02-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Éphrine A3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Éphrines", "url": "https://questionsmedicales.fr/mesh/D036342", "about": { "@type": "MedicalCondition", "name": "Éphrines", "code": { "@type": "MedicalCode", "code": "D036342", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.500" } } }, "about": { "@type": "MedicalCondition", "name": "Éphrine A3", "alternateName": "Ephrin-A3", "code": { "@type": "MedicalCode", "code": "D036384", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elena B Pasquale", "url": "https://questionsmedicales.fr/author/Elena%20B%20Pasquale", "affiliation": { "@type": "Organization", "name": "Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. elenap@sbpdiscovery.org." } }, { "@type": "Person", "name": "Katsuaki Ieguchi", "url": "https://questionsmedicales.fr/author/Katsuaki%20Ieguchi", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp." } }, { "@type": "Person", "name": "Yoshiro Maru", "url": "https://questionsmedicales.fr/author/Yoshiro%20Maru", "affiliation": { "@type": "Organization", "name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp." } }, { "@type": "Person", "name": "Stamatios Theocharis", "url": "https://questionsmedicales.fr/author/Stamatios%20Theocharis", "affiliation": { "@type": "Organization", "name": "First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece." } }, { "@type": "Person", "name": "Liu Yang", "url": "https://questionsmedicales.fr/author/Liu%20Yang", "affiliation": { "@type": "Organization", "name": "Department of Ophthalmology, Peking University First Hospital, Beijing, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interpreting and assessing confidence in network meta-analysis results: an introduction for clinicians.", "datePublished": "2022-06-01", "url": "https://questionsmedicales.fr/article/35641661", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00540-022-03072-5" } }, { "@type": "ScholarlyArticle", "name": "Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis.", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35613849", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/ebmental-2022-300457" } }, { "@type": "ScholarlyArticle", "name": "Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis.", "datePublished": "2024-08-30", "url": "https://questionsmedicales.fr/article/39281677", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1445814" } }, { "@type": "ScholarlyArticle", "name": "A Network Meta-Analysis on the Effects of Different Exercise Types in Patients With COPD.", "datePublished": "2024-08-24", "url": "https://questionsmedicales.fr/article/38503464", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4187/respcare.11476" } }, { "@type": "ScholarlyArticle", "name": "Management of de Quervain Tenosynovitis: A Systematic Review and Network Meta-Analysis.", "datePublished": "2023-10-02", "url": "https://questionsmedicales.fr/article/37889490", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2023.37001" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Éphrines", "item": "https://questionsmedicales.fr/mesh/D036342" }, { "@type": "ListItem", "position": 5, "name": "Éphrine A3", "item": "https://questionsmedicales.fr/mesh/D036384" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Éphrine A3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Éphrine A3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Éphrine A3", "description": "Comment diagnostiquer une anomalie d'éphrine A3 ?\nQuels examens sont recommandés pour évaluer l'éphrine A3 ?\nY a-t-il des biomarqueurs associés à l'éphrine A3 ?\nQuels symptômes peuvent indiquer un problème avec l'éphrine A3 ?\nPeut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=7#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Éphrine A3", "description": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?\nL'éphrine A3 est-elle liée à des maladies spécifiques ?\nComment l'éphrine A3 affecte-t-elle le système nerveux ?\nDes troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?\nL'éphrine A3 influence-t-elle le développement cérébral ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=7#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Éphrine A3", "description": "Peut-on prévenir les troubles liés à l'éphrine A3 ?\nY a-t-il des facteurs environnementaux influençant l'éphrine A3 ?\nComment le mode de vie affecte-t-il l'éphrine A3 ?\nDes conseils nutritionnels peuvent-ils aider ?\nL'éducation prénatale peut-elle prévenir des troubles ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=7#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Éphrine A3", "description": "Quels traitements ciblent l'éphrine A3 ?\nPeut-on modifier l'expression de l'éphrine A3 ?\nY a-t-il des essais cliniques sur l'éphrine A3 ?\nQuels médicaments peuvent affecter l'éphrine A3 ?\nL'éphrine A3 peut-elle être une cible thérapeutique ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=7#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Éphrine A3", "description": "Quelles complications peuvent survenir avec l'éphrine A3 ?\nL'éphrine A3 est-elle impliquée dans des cancers ?\nDes troubles cognitifs peuvent-ils être des complications ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive avec l'éphrine A3 ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=7#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Éphrine A3", "description": "Quels sont les facteurs de risque pour l'éphrine A3 ?\nL'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?\nLes toxines environnementales affectent-elles l'éphrine A3 ?\nLe stress peut-il influencer l'éphrine A3 ?\nY a-t-il des prédispositions génétiques pour l'éphrine A3 ?", "url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Network+Meta-Analysis&page=7#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie d'éphrine A3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour détecter des anomalies." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour évaluer l'éphrine A3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'immunohistochimie et la PCR sont souvent utilisés pour évaluer l'expression de l'éphrine A3." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à l'éphrine A3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'éphrine A3 elle-même peut servir de biomarqueur dans certaines pathologies neurologiques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec l'éphrine A3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques ou des anomalies de développement peuvent indiquer un problème." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie cérébrale peut aider à visualiser des anomalies associées à des dysfonctionnements de l'éphrine A3." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles cognitifs, des problèmes de coordination et des retards de développement." } }, { "@type": "Question", "name": "L'éphrine A3 est-elle liée à des maladies spécifiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies d'éphrine A3 sont associées à des maladies neurodégénératives et des cancers." } }, { "@type": "Question", "name": "Comment l'éphrine A3 affecte-t-elle le système nerveux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elle joue un rôle dans la formation des synapses et la plasticité neuronale, influençant le comportement." } }, { "@type": "Question", "name": "Des troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles du comportement." } }, { "@type": "Question", "name": "L'éphrine A3 influence-t-elle le développement cérébral ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est essentielle pour le développement normal des circuits neuronaux dans le cerveau." } }, { "@type": "Question", "name": "Peut-on prévenir les troubles liés à l'éphrine A3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par une détection précoce et une intervention dans les cas à risque." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux influençant l'éphrine A3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs environnementaux comme la nutrition et les toxines peuvent influencer son expression." } }, { "@type": "Question", "name": "Comment le mode de vie affecte-t-il l'éphrine A3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut favoriser une expression normale de l'éphrine A3 et réduire les risques." } }, { "@type": "Question", "name": "Des conseils nutritionnels peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en nutriments peut soutenir la santé neuronale et l'éphrine A3." } }, { "@type": "Question", "name": "L'éducation prénatale peut-elle prévenir des troubles ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation prénatale sur les risques environnementaux peut aider à prévenir des troubles liés à l'éphrine A3." } }, { "@type": "Question", "name": "Quels traitements ciblent l'éphrine A3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments ciblant les voies de signalisation peuvent être envisagés." } }, { "@type": "Question", "name": "Peut-on modifier l'expression de l'éphrine A3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des approches pharmacologiques peuvent moduler l'expression de l'éphrine A3 dans certaines conditions." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur l'éphrine A3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques sont en cours pour évaluer des traitements ciblant l'éphrine A3 dans diverses pathologies." } }, { "@type": "Question", "name": "Quels médicaments peuvent affecter l'éphrine A3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments anticancéreux et neuroprotecteurs peuvent influencer l'activité de l'éphrine A3." } }, { "@type": "Question", "name": "L'éphrine A3 peut-elle être une cible thérapeutique ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en raison de son rôle dans diverses maladies, elle est considérée comme une cible thérapeutique potentielle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'éphrine A3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications neurologiques et des troubles de développement peuvent survenir en cas d'anomalies." } }, { "@type": "Question", "name": "L'éphrine A3 est-elle impliquée dans des cancers ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies d'éphrine A3 sont associées à certains types de cancers, notamment le gliome." } }, { "@type": "Question", "name": "Des troubles cognitifs peuvent-ils être des complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles cognitifs sévères." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications implique des traitements symptomatiques et des interventions ciblées." } }, { "@type": "Question", "name": "Y a-t-il des risques de récidive avec l'éphrine A3 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des risques de récidive peuvent exister dans les cas de cancers associés à des anomalies d'éphrine A3." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'éphrine A3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques, environnementaux et le mode de vie peuvent influencer le risque d'anomalies." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les toxines environnementales affectent-elles l'éphrine A3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut perturber l'expression de l'éphrine A3." } }, { "@type": "Question", "name": "Le stress peut-il influencer l'éphrine A3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la signalisation de l'éphrine A3 et la santé neuronale." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour l'éphrine A3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent prédisposer les individus à des troubles liés à l'éphrine A3." } } ] } ] }

Sources (10000 au total)

Interpreting and assessing confidence in network meta-analysis results: an introduction for clinicians.

We aimed to provide clinicians with introductory guidance for interpreting and assessing confidence in on Network meta-analysis (NMA) results.... We reviewed current literature on NMA and summarized key points.... Network meta-analysis (NMA) is a statistical method for comparing the efficacy of three or more interventions simultaneously in a single analysis by synthesizing both direct and indirect evidence acro... We recommend a careful approach to interpreting NMA results and the validity of an NMA depends on its underlying statistical assumptions and the quality of the evidence used in the NMA....

Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis.

A network meta-analysis (NMA) usually assesses multiple outcomes across several treatment comparisons. The... We developed this tool following the recommendations on the communication of benefit-risk information from the available literature. We collected and implemented feedback from researchers, statisticia... We present the... The...

Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis.

Previous studies comparing the efficacy and safety of different treatment regimens for lupus nephritis are scarce. Moreover, confounding factors such as the duration of follow-up were hardly adjusted ... To rigorously investigate the efficacy and safety of biologics in patients with lupus nephritis using Bayesian network meta-regression analyses that adjust for the follow-up period, in order to provid... Databases comprising PubMed, Embase, MedlinePlus, Cochrane Library, Google Scholars, and Scopus were retrieved for eligible articles from inception to February 29, 2024. The primary endpoint was the c... Ten studies involving 2138 patients and 11 treatment regimens were ultimately included. In the original analysis, for the primary endpoint, compared to the control group, obinutuzumab (22.6 months), a... Considering the efficacy and safety and "time window" phenomenon, we recommend obinutuzumab as the preferred treatment for LN. Certainly, more rigorous head-to-head clinical trials are warranted to va...

A Network Meta-Analysis on the Effects of Different Exercise Types in Patients With COPD.

This study aimed to compare and rank the effects of aerobic exercise, resistance training, endurance training, and high-intensity interval training in COPD by network meta-analysis.... PubMed, Cochrane, Embase, and the Web of Science were searched to identify randomized controlled trials that investigated the effects of exercise training on COPD. The search period began on the date ... This study included a total of 27 studies that involved 1,415 subjects. The network meta-analysis findings indicated that high-intensity interval training was the most-effective intervention for impro... The findings of this study suggest that high-intensity interval training may be more effective than endurance exercise, resistance exercise, and aerobic exercise in improving the 6-min walk distance, ...

Management of de Quervain Tenosynovitis: A Systematic Review and Network Meta-Analysis.

There is a plethora of treatment options for patients with de Quervain tenosynovitis (DQT), but there are limited data on their effectiveness and no definitive management guidelines.... To assess and compare the effectiveness associated with available treatment options for DQT to guide musculoskeletal practitioners and inform guidelines.... Medline, Embase, PubMed, Cochrane Central, Scopus, OpenGrey.eu, and WorldCat.org were searched for published studies, and the World Health Organization International Clinical Trials Registry Platform,... All randomized clinical trials assessing the effectiveness of any intervention for the management of DQT.... This study was prospectively registered on PROSPERO and conducted and reported per Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension Statement for Reporting of Systematic Re... Pairwise and network meta-analyses were performed for patient-reported pain using a visual analogue scale (VAS) and for function using the quick disabilities of the arm, shoulder, and hand (Q-DASH) sc... A total of 30 studies with 1663 patients (mean [SD] age, 46 [7] years; 80% female) were included, of which 19 studies were included in quantitative analyses. From the pairwise meta-analyses, based on ... This network meta-analysis found that adding a short period of thumb spica immobilization to CSI was associated with statistically but not clinically significant short- and mid-term benefits. These fi...

A network meta-analysis of different acupuncture modalities in the treatment of bronchial asthma.

Glucocorticoids and Beta-2 receptor agonists are commonly used for the treatment of asthma in clinical practice, while these agents are accompanied by adverse reactions of different kinds. Studies hav... The following databases were searched for randomized controlled trials (RCTs) on acupuncture for the treatment of bronchial asthma from database inception to August 26, 2022: PubMed, Embase, The Cochr... A total of 8,693 relevant studies were found, and 30 RCTs were included, involving 2,722 patients with bronchial asthma and eight acupuncture modalities: manual acupuncture, moxibustion, electroacupun... Acupoint application has evident merits in improving the clinical response rate and pulmonary function, while acupoint catgut embedding can improve other secondary indicators. For the clinical treatme...

Exercise for sarcopenia in older people: A systematic review and network meta-analysis.

Sarcopenia is a serious public health concern among older adults worldwide. Exercise is the most common intervention for sarcopenia. This study aimed to compare the effectiveness of different exercise... Randomized controlled trials (RCTs) that examined the effectiveness of exercise interventions on patient-important outcomes for older adults with sarcopenia were eligible. We systematically searched M... Our search identified 5988 citations, of which 42 RCTs proved eligible with 3728 participants with sarcopenia (median age: 72.9 years, female: 73.3%) with a median follow-up of 12 weeks. We are intere... In older adults with sarcopenia, high or moderate certainty evidence showed that resistance exercise with or without nutrition and the combination of resistance exercise with aerobic and balance train...

A systematic review and network meta-analysis of the effectiveness of sclerotherapy for venous malformation.

Sclerotherapy for venous malformation has been widely used; however, no guidelines are available to assess the effectiveness of different sclerotherapy agents. We conducted a systematic review and net... Three electronic databases were searched from their inception (1950) to April 29, 2021. Studies comparing the effectiveness of different sclerotherapy agents were included. The risk of bias within and... Seven studies with 547 patients in six arms were included in the present study. We defined the response and complete response as two separate outcomes. Significant differences were observed in four co... Ethanol showed a significantly better response statistically compared with the other agents. However, ethanol had also resulted in the highest incidence of complications. Pingyangmycin showed the seco...